Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-Week,Multi-Center,Randomized,Double-Blind,Placebo-Controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106.

Next Previous
Trial Profile

A 52-Week,Multi-Center,Randomized,Double-Blind,Placebo-Controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amilomotide (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

Most Recent Events

  • 18 Jul 2012 NCT01023685 reports status of extension trial as completed.
  • 18 Jul 2012 NCT01023685 reports status of extension trial as completed.
  • 16 Nov 2011 Planned trial end date (Feb 2012) added as reported by ClinicalTrials.gov record (NCT01023685).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top